Radius Health (RDUS) Tops Q4 EPS by 51c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
February 28, 2019 4:06 PM ESTTYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Companys guidance of $95-98 million.
Elacestrants Phase 3 study was initiated at the end of 2018 and is open for enrollment.
Radius maintains its financial guidance for 2019 with full-year TYMLOS U.S. net sales expected to be between $155 to $175 million and year-end cash, cash equivalents & investments expected to exceed $100 million.
Conference call scheduled for 4:30 p.m. ET today... More
